keyword
MENU ▼
Read by QxMD icon Read
search

Relapsed diffuse large b cell lymphoma

keyword
https://www.readbyqxmd.com/read/28327893/bcl2-expression-but-not-myc-and-bcl2-coexpression-predicts-survival-in-elderly-patients-with-diffuse-large-b-cell-lymphoma-independently-of-cell-of-origin-in-the-phase-3-lnh03-6b-trial
#1
T Petrella, C Copie-Bergman, J Brière, R Delarue, F Jardin, P Ruminy, C Thieblemont, M Figeac, D Canioni, P Feugier, B Fabiani, K Leroy, M Parrens, M André, C Haioun, G A Salles, P Gaulard, H Tilly, J P Jais, T J Molina
Background: Our aim was to evaluate whether the cell of origin (COO) as defined by the Hans algorithm and MYC/BCL2 coexpression, which are the two main biological risk factors in elderly patients treated with rituximab, cyclophosphamide, doxorubicin hydrochloride, vincristine, and prednisolone (R-CHOP), maintain their prognostic value in a large prospective clinical trial. Patients and Methods: We evaluated 285 paraffin-embedded samples from patients (60-80 years of age) enrolled in the Lymphoma Study Association (LYSA) trial LNH03-6B who were treated with R-CHOP...
January 24, 2017: Annals of Oncology: Official Journal of the European Society for Medical Oncology
https://www.readbyqxmd.com/read/28321641/transformed-follicular-lymphoma-tfl-consolidation-therapy-may-improve-survival
#2
E Elhassadi, R Flavin, P Browne, E Conneally, P Hayden, F Quinn, E Higgins, E Vandenberghe
PURPOSE: Retrospective study to evaluate the outcome of patients with transformed follicular lymphoma (tFL) treated with rituximab-containing chemotherapy and consolidation. PATIENTS AND METHODS: Patients diagnosed with tFL from 2003 to 2013 treated with consolidation therapy with last follow-up in December 2015 were identified from the institutional lymphoma database and included in this study. Data collected included age, gender, stage, interval to tFL diagnosis, R-IPI score, histological diagnosis and therapy...
March 21, 2017: Irish Journal of Medical Science
https://www.readbyqxmd.com/read/28295729/targeting-of-b-cell-receptor-signalling-in-b-cell-malignancies
#3
M Jerkeman, M Hallek, M Dreyling, C Thieblemont, E Kimby, L Staudt
Pharmacological agents that inhibit enzymes of the B-cell receptor (BCR) pathway are of increasing importance in the treatment of B-cell malignancies. These include inhibitors of Bruton tyrosine kinase (BTK), phosphatidylinositol 3-kinase (PI3K), splenic tyrosine kinase and protein kinase Cβ. Two agents are already approved in the USA and Europe: ibrutinib, a BTK inhibitor, for the treatment of chronic lymphatic leukaemia (CLL), mantle cell lymphoma (MCL) and Waldenström's macroglobulinemia; and idelalisib, a PI3Kδ inhibitor, for the treatment of CLL and follicular lymphoma...
March 14, 2017: Journal of Internal Medicine
https://www.readbyqxmd.com/read/28291388/lymphoma-remissions-caused-by-anti-cd19-chimeric-antigen-receptor-t-cells-are-associated-with-high-serum-interleukin-15-levels
#4
James N Kochenderfer, Robert P T Somerville, Tangying Lu, Victoria Shi, Adrian Bot, John Rossi, Allen Xue, Stephanie L Goff, James C Yang, Richard M Sherry, Christopher A Klebanoff, Udai S Kammula, Marika Sherman, Arianne Perez, Constance M Yuan, Tatyana Feldman, Jonathan W Friedberg, Mark J Roschewski, Steven A Feldman, Lori McIntyre, Mary Ann Toomey, Steven A Rosenberg
Purpose T cells genetically modified to express chimeric antigen receptors (CARs) targeting CD19 (CAR-19) have potent activity against acute lymphoblastic leukemia, but fewer results supporting treatment of lymphoma with CAR-19 T cells have been published. Patients with lymphoma that is chemotherapy refractory or relapsed after autologous stem-cell transplantation have a grim prognosis, and new treatments for these patients are clearly needed. Chemotherapy administered before adoptive T-cell transfer has been shown to enhance the antimalignancy activity of adoptively transferred T cells...
March 14, 2017: Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology
https://www.readbyqxmd.com/read/28290728/diffuse-large-b-cell-lymphoma-in-the-elderly-standard-treatment-and-new-perspectives
#5
Chiappella Annalisa, Alessia Castellino, Maura Nicolosi, Elisa Santambrogio, Umberto Vitolo
Diffuse large B-cell lymphoma (DLBCL) is the most common histotype in non Hodgkin lymphoma, with a peak incidence in the sixth decade. The standard treatment for elderly FIT DLBCL patients is Rituximab-CHOP; in unfit and frail patients, chemotherapy at reduced intensity should be considered. Areas covered: In this article, we will review use of standard therapies and new drugs investigated such as immonomudulating agents (IMiDs), Bruton Tyrosine Kinase (BTK), in fit, unfit, frail and very elderly DLCBL patients...
March 14, 2017: Expert Review of Hematology
https://www.readbyqxmd.com/read/28278731/treatment-of-initial-parenchymal-central-nervous-system-involvement-in-systemic-aggressive-b-cell-lymphoma
#6
Marcel Nijland, Anne Jansen, Jeanette K Doorduijn, Roelien H Enting, Jacoline E C Bromberg, Hanneke C Kluin-Nelemans
Central nervous system (CNS) involvement in systemic B-cell non-Hodgkin lymphoma (B-NHL) at diagnosis (sysCNS) is rare. We investigated the outcome of 21 patients with sysCNS, most commonly diffuse large B-cell lymphoma, treated with high dose methotrexate (HD-MTX) and R-CHOP. The median number of cycles of HD-MTX and R-CHOP was 4 (range 1-8) and 6 (range 0-8), respectively. Consolidative whole brain radiotherapy (WBRT) was given to 33% (7/21) patients. With a median follow-up of 44 months the 3-year progression free survival (PFS) and overall survival (OS) were 45% (95%CI 34-56%) and 49% (95%CI 38-60%), respectively...
February 6, 2017: Leukemia & Lymphoma
https://www.readbyqxmd.com/read/28272240/a-92-year-old-man-with-primary-cutaneous-diffuse-large-b-cell-non-hodgkin-s-lymphoma-manifesting-as-a-giant-scalp-mass-a-case-report
#7
Chenlong Liao, Min Yang, Pengfei Liu, Wenchuan Zhang
RATIONALE: Primary cutaneous non-Hodgkin's lymphoma (NHL) is an uncommon entity, representing 10% of all extranodal NHLs. Among all cutaneous sites, the scalp is a rare site of representation. PATIENT CONCERNS: A 92-year-old Chinese man visited our hospital with a multiple-nodular huge scalp mass on the right parieto-occipital regions. The mass was of 7-month duration and progressively enlarging in size. DIAGNOSES: On the basis of the result of biopsy, diffuse large B-cell NHL was diagnosed...
March 2017: Medicine (Baltimore)
https://www.readbyqxmd.com/read/28271414/pediatric-follicular-lymphoma-in-japan
#8
Ryoji Kobayashi, Fumiko Tanaka, Atsuko Nakazawa, Jun-Ichi Ueyama, Shosuke Sunami, Tetsuo Mitsui, Yuhki Koga, Takeshi Mori, Tomoo Osumi, Reiji Fukano, Kentaro Ohki, Masahiro Sekimizu, Naoto Fujita, Michi Kamei, Tetsuya Mori
Follicular lymphoma (FL) is quite rare in children. There have been only two major reports on pediatric FL. The present retrospective study on pediatric FL in Japan, including FL with diffuse large B cell lymphoma (DLBCL), analyzed data from 1991 to 2014. Twenty-two patients with pediatric FL were analyzed. Sixteen patients were boys and six were girls. Median age of onset was 9 years (range 4-17 years). In 11 patients, DLBCL co-existed with FL. The initial lesions involved cervical lesions in 16 patients, and the abdomen in six...
March 7, 2017: International Journal of Hematology
https://www.readbyqxmd.com/read/28267593/phase-ii-study-of-yttrium-90-ibritumomab-tiuxetan-plus-high-dose-beam-for-non-hodgkin-lymphoma-the-role-of-histology
#9
Amrita Y Krishnan, Joycelynne Palmer, Auayporn P Nademanee, Robert Chen, Leslie L Popplewell, Ni-Chun Tsai, James F Sanchez, Jennifer Simpson, Ricardo Spielberger, Dave Yamauchi, Stephen J Forman
Standard-dose (90)yttrium-ibritumomab tiuxetan (0.4 mci/kg) (Zevalin) together with high-dose BEAM (BCNU, etoposide, cytarabine, and melphalan) (Z-BEAM) has been shown to be a well-tolerated autologous hematopoietic stem cell transplantation (autoHCT) preparative regimen for non-Hodgkin lymphoma. We report the outcomes of a single-center, single-arm phase II trial of Z-BEAM conditioning in high-risk CD20(+) non-Hodgkin lymphoma histologic strata: diffuse large B cell (DLBCL), mantle cell (MCL), follicular (FL), and transformed (TF)...
March 3, 2017: Biology of Blood and Marrow Transplantation
https://www.readbyqxmd.com/read/28245387/-clinical-analysis-of-153-cases-of-refractory-relapsed-diffuse-large-b-cell-lymphoma
#10
Dan-Dan Zou, Bo Guo, Peng Yin, Ye Tian, Hong-Li Zhu
OBJECTIVE: To analyze the clinical features and treatment methods of refractory/relapsed diffuse large B cell lymphoma (DLBCL) patients, and to explore the curative effect and the main factors affecting prognosis. METHODS: Clinical data of 1043 cases of DLBCL in our hospital from January 2008 to April 2016 were retrospectively analyzed, then the clinical data of 153 patients with refractory/relapsed lymphoma were selected and analyzed for determing the relationship of the related factors with therapeutic effect and prognosis...
February 2017: Zhongguo Shi Yan Xue Ye Xue za Zhi
https://www.readbyqxmd.com/read/28238096/clinical-impact-of-galectin-3-in-newly-diagnosed-t-15-17-q22-q21-pml-rara-acute-promyelocytic-leukemia-treated-with-all-trans-retinoic-acid-and-arsenic-trioxide-based-regimens
#11
Na Gao, Xue-Xia Wang, Jian-Rong Sun, Wen-Zheng Yu, Xi-Zhi Li
Increased galectin-3 expression has been currently showed to be associated with poor prognosis in some hematological malignancies, such as acute myeloid leukemia, diffuse large B cell lymphoma. However, little is known about the clinical significance of galectin-3 in patients with acute promyelocytic leukemia (APL). We investigated the concentration of serum galectin-3 and characterized the relationship between galectin-3 and outcome in patients with APL. Higher galectin-3 levels were detected in patients with APL compared with the healthy controls (p < 0...
February 25, 2017: Annals of Hematology
https://www.readbyqxmd.com/read/28237865/the-number-of-extranodal-sites-assessed-by-pet-ct-scan-is-a-powerful-predictor-of-cns-relapse-for-patients-with-diffuse-large-b-cell-lymphoma-an-international-multicenter-study-of-1532-patients-treated-with-chemoimmunotherapy
#12
Tarec Christoffer El-Galaly, Diego Villa, Thomas Yssing Michaelsen, Martin Hutchings, Nabegh George Mikhaeel, Kerry J Savage, Laurie H Sehn, Sally Barrington, Jakob W Hansen, Daniel Smith, Kirsty Rady, Karen J Mylam, Thomas S Larsen, Staffan Holmberg, Maja B Juul, Sabrina Cordua, Michael R Clausen, Kristina B Jensen, Hans E Johnsen, John F Seymour, Joseph M Connors, Peter de Nully Brown, Martin Bøgsted, Chan Y Cheah
PURPOSE: Development of secondary central nervous system involvement (SCNS) in patients with diffuse large B-cell lymphoma is associated with poor outcomes. The CNS International Prognostic Index (CNS-IPI) has been proposed for identifying patients at greatest risk, but the optimal model is unknown. METHODS: We retrospectively analysed patients with diffuse large B-cell lymphoma diagnosed between 2001 and 2013, staged with PET/CT and treated with R-CHOP(-like) regimens...
April 2017: European Journal of Cancer
https://www.readbyqxmd.com/read/28219694/lenalidomide-maintenance-in-patients-with-relapsed-diffuse-large-b-cell-lymphoma-who-are-not-eligible-for-autologous-stem-cell-transplantation-an-open-label-single-arm-multicentre-phase-2-trial
#13
Andrés J M Ferreri, Marianna Sassone, Francesco Zaja, Alessandro Re, Michele Spina, Alice Di Rocco, Alberto Fabbri, Caterina Stelitano, Maurizio Frezzato, Chiara Rusconi, Renato Zambello, Suzana Couto, Yan Ren, Annalisa Arcari, Giovanni Bertoldero, Alessandro Nonis, Lydia Scarfò, Teresa Calimeri, Caterina Cecchetti, Marianna Chiozzotto, Silvia Govi, Maurilio Ponzoni
BACKGROUND: Patients with relapsed diffuse large B-cell lymphoma (DLBCL) not eligible for autologous stem cell transplantation (ASCT) or having relapse after ASCT have a low likelihood of cure. Single-drug maintenance after salvage therapy might be an attractive strategy to prolong survival in these patients. Lenalidomide is a suitable candidate for long-lasting maintenance as it is an oral drug, active against DLBCL that can be taken for years with an acceptable toxicity profile. We designed a study to investigate safety and efficacy of lenalidomide maintenance in patients with chemosensitive relapse of DLBCL not eligible for ASCT or having relapse after ASCT...
February 16, 2017: Lancet Haematology
https://www.readbyqxmd.com/read/28218382/primary-cutaneous-non-hodgkin-lymphoma-results-of-a-retrospective-analysis-in-the-light-of-the-recent-ilrog-guidelines
#14
Sara Pedretti, Mauro Urpis, Carla Leali, Paolo Borghetti, Liliana Baushi, Raffaella Sala, Alessandra Tucci, Diana Greco, Nadia Pasinetti, Luca Triggiani, Giuseppe Rossi, Piergiacomo Calzavara-Pinton, Stefano Maria Magrini, Michela Buglione
PURPOSE: To analyze clinical outcome, local response, survival and toxicity in patients with primary cutaneous lymphoma (PCL) treated with radiotherapy. METHODS: From 1995 to 2014, 112 patients were treated. B-cell lymphomas (CBCLs; n = 86) and T-cell lymphomas (CTCLs; n = 23) were analyzed separately. Clinical and therapeutic characteristics (age, sex, histology, primary treatment and radiotherapy modality) were related to response to treatment, survival and toxicity...
February 14, 2017: Tumori
https://www.readbyqxmd.com/read/28152924/diffuse-large-b-cell-lymphoma-a-single-institution-experience-of-patient-outcomes
#15
Rasna Gupta, Sindu Mary Kanjeekal, Mohammed Jarrar, Amin Kay, John Mathews, Indryas Lemma Woldie, Caroline M Hamm
271 Background: The Windsor Regional Cancer Program (WRCP) was determined to have consistently been a top performer in time to treatment of diffuse large B cell lymphoma in this Canadian province (http://www.csqi.on.ca/by_type_of_cancer/lymphoma/lymphoma_treatment/). We endeavored to determine whether faster time to diagnosis and treatment for diffuse large B-cell lymphoma (DLBCL) influenced the IPI score (International Prognostic Score), thereby predicting an improved clinical outcome in these presenting patients...
March 2016: Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology
https://www.readbyqxmd.com/read/28126962/safety-and-efficacy-of-abexinostat-a-pan-histone-deacetylase-inhibitor-in-non-hodgkin-lymphoma-and-chronic-lymphocytic-leukemia-results-of-a-phase-2-study
#16
Vincent Ribrag, Won Seog Kim, Reda Bouabdallah, Soon Thye Lim, Bertrand Coiffier, Arpad Illes, Bernard Lemieux, Martin J S Dyer, Fritz Offner, Zakia Felloussi, Ioana Kloos, Ying Luan, Remus Vezan, Thorsten Graef, Franck Morschhauser
Histone deacetylase inhibitors are members of a class of epigenetic drugs that have proven activity in T-cell malignancies, but little is known about their efficacy in B-cell lymphomas. Abexinostat is an orally available hydroxamate-containing histone deacetylase inhibitor that differs from approved inhibitors; its unique pharmacokinetic profile and oral dosing schedule, twice daily 4 hours apart, allows for continuous exposure at concentrations required for efficient tumor cell killing. In this phase 2 study, patients with relapsed/refractory non-Hodgkin lymphoma or chronic lymphocytic leukemia received oral abexinostat at 80 mg BID for 14 days of a 21-day cycle and continued until progressive disease or unacceptable toxicity...
January 25, 2017: Haematologica
https://www.readbyqxmd.com/read/28123744/complete-response-to-azacitidine-priming-and-nab-paclitaxel-in-non-hodgkin-lymphoma-resistant-to-biochemotherapy
#17
Randy C Bowen, Andrew W Hahn, Thomas W Butler, Hung T Khong
The standard of care for first-line therapy in diffuse large B-cell lymphoma (DLBCL) is the rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone (R-CHOP) regimen. For patients who fail to respond, have an incomplete response or relapse, numerous effective options exists besides salvage cisplatin-based regimen and autologous stem cell therapy. Even with this approach, the outcome remains very poor for this group of patients. The present case illustrates a 55-year-old woman diagnosed with DLBCL, who experienced an early incomplete response, later progression during treatment with the R-CHOP regimen...
January 2017: Molecular and Clinical Oncology
https://www.readbyqxmd.com/read/28122892/safety-efficacy-and-pharmacokinetics-of-humanized-anti-cd52-monoclonal-antibody-alemtuzumab-in-japanese-patients-with-relapsed-or-refractory-b-cell-chronic-lymphocytic-leukemia
#18
Kenichi Ishizawa, Noriko Fukuhara, Chiaki Nakaseko, Shigeru Chiba, Michinori Ogura, Akihiko Okamoto, Yoshinori Sunaga, Kensei Tobinai
OBJECTIVE: To evaluate the safety, efficacy and pharmacokinetics of alemtuzumab in Japanese patients, we conducted a phase I study in patients with relapsed or refractory B-cell chronic lymphocytic leukemia. METHODS: Six patients received alemtuzumab by intravenous infusion every other day three times a week for 12 weeks. The dose was gradually escalated on daily basis (3, 10 and then 30 mg) until the patient tolerated. The primary objective was to evaluate the safety of alemtuzumab in Japanese patients and the secondary objectives were to evaluate the overall response rate and the pharmacokinetics...
January 2017: Japanese Journal of Clinical Oncology
https://www.readbyqxmd.com/read/28118604/tenovin-6-inhibits-proliferation-and-survival-of-diffuse-large-b-cell-lymphoma-cells-by-blocking-autophagy
#19
Hongfeng Yuan, Meilan He, Fan Cheng, Rosemary Bai, Suzane Ramos da Silva, Ricardo C T Aguiar, Shou-Jiang Gao
Diffuse large B-cell lymphoma (DLBCL) is one of the most aggressive non-Hodgkin lymphomas. It is curable but one-third of cases are refractory to therapy or relapse after initial response highlighting the urgent need for developing novel therapeutic approaches. Targeting sirtuins, particularly SIRT1 by genetic approaches or using pharmaceutical inhibitor tenovin-6, has shown promising therapeutic potential in various hematopoietic malignancies. However, it remains unknown whether these approaches are effective for DLBCL...
January 19, 2017: Oncotarget
https://www.readbyqxmd.com/read/28112344/-tonsillar-actinomycosis-mimicking-relapse-of-diffuse-large-b-cell-non-hodgkin-lymphoma
#20
Frederico Carvalho de Medeiros, Fernando Carvalho de Medeiros
No abstract text is available yet for this article.
October 2016: Revista Chilena de Infectología: órgano Oficial de la Sociedad Chilena de Infectología
keyword
keyword
101126
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"